Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scanner could slash stroke diagnosis time

NCT ID NCT05458908

Diagnosis Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special CT scan done in the procedure room can accurately detect bleeding in the brain of stroke patients. The goal is to speed up diagnosis and treatment by avoiding extra trips to the regular CT scanner. 252 adults with stroke symptoms were enrolled to compare the new scan with the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

252 people

The number who actually took part.

Started

Oct 2022

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed Consent as documented by signature or fulfilling the criteria for emergency or deferral consent * Patients with symptoms suggestive of ischemic stroke (NIHSS ≥ 7) or suggestive of haemorrhagic stroke with a cranial non-contrast MDCT and a feasible non-contrast syngo DynaCT Sine Spin within 4 hours * Patient presenting within 24 hours of last seen well * Patients presenting directly to the treating hospital (i.e. mothership patients) OR transfer patients with the indication for repeated imaging according to the standard operation procedures of the treating hospital * Age above 18 years * Agreement of treating physician to perform non-contrast syngo DynaCT Sine Spin Exclusion Criteria: * Severe metal artifacts on initial MDCT imaging * Planned invasive interventions between MDCT and FDCT scan * Clinical deterioration between MDCT and FDCT scan (i.e. an increase of the NIHSS of more than 4 points) * Evidence of an ongoing pregnancy prior to enrollment. A negative pregnancy test before enrollment is required for all women with child-bearing potential

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemorrhagic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemorrhagic stroke Intracranial Hemorrhages ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stroke

Contacts and locations

Locations

  • AdvocateAurora Health

    Chicago, Illinois, 60068, United States

  • CHRU de Tours

    Tours, 37000, France

  • HUS

    Helsinki, 00290, Finland

  • Hospital Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Inselspital Bern

    Bern, Switzerland

  • Kantonsspital Luzern

    Lucerne, Switzerland

  • Mount Sinai Health System

    New York, New York, 10029, United States

  • New York University Langone Health

    New York, New York, 10016, United States

  • Nortshore University Health System

    Chicago, Illinois, 60201, United States

  • Semmes Murphy Clinic

    Memphis, Tennessee, 38120, United States

  • Swedish Medical Center

    Denver, Colorado, 80210, United States

  • University Hospital Basel

    Basel, Switzerland

  • University of Virginia Health System

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.